Prostatis Group’s Target TGT Stock Holding History

Prostatis Group’s Portfolio TGT Stock Details TGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$222K	Buy	+1,699	New	+$216K	0.05%	173
2023 Q3	–	Sell	-59,751	Closed	-$59.8K	–	225
2023 Q2	$59.8K	Buy	+59,751	New	+$8.87M	0.03%	164

Other funds holding TGT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Prostatis Group's TGT Position: Q2 2026 in Review

Prostatis Group opened a new position in Target (TGT) in Q2 2026: 1,699 shares worth $222K. The stake represents 0.05% of the portfolio and ranks #173 among its holdings. This is a return to the name: Prostatis Group previously reported a position in TGT as recently as Q2 2023.

Prostatis Group first reported a position in TGT in Q2 2023 and has held it in 2 quarters since. 1,886 funds tracked by Wall St. Rank hold TGT as of Q2 2026.

Prostatis Group held 1,699 shares of Target worth $222K as of Q2 2026.
Target was a new Prostatis Group position in Q2 2026.
Target made up 0.05% of Prostatis Group's portfolio in Q2 2026, its #173 holding.
Prostatis Group first reported a position in Target in Q2 2023 and has held it in 2 quarters since.
1,886 funds tracked by Wall St. Rank held Target as of Q2 2026.

Based on Prostatis Group's 13F filing for Q2 2026, filed 14 Aug 2026.